Replies to post #32359 on Biotech Values

[gofishmarko]

Re : Sepsis article

>>> Sepsis/Just read this article and thought it is interesting...! <<<

Agreed. I hadn't read about the PIRO model before and it's just the kind of modeling study that I'd like to see done for other indications:

"Addressing clinical indices of sepsis, Mitchell Levy (Rhode Island Hospital, Providence, RI, USA) explored the characterization of sepsis using the proposed PIRO (Predisposition, Infection, Response, Organ Dysfunction) model. This framework takes into account an individual’s predisposition to sepsis (including comorbidities and genetic and epigenetic variations), the infectious agent and site of infection, the host response to infection (such as levels of specific cytokines), and organ dysfunction. An observational study to verify PIRO is ongoing that aims to enroll 1000 septic patients at 10 centers and collect a wide range of information from time of presentation in the emergency department to recovery. The PIRO system allows for integration of clinical, translational, and basic scientific discoveries and promises to more accurately predict outcomes and responses to therapy for individual patients."

[DewDiligence]

Thanks for the sepsis post. Those are clearly not the kinds of results that will help make Xigris a big-selling drug. The field remains wide open.